文献速递类风湿关节炎脊柱关节炎

英格兰炎症性关节炎患者的镇痛药处方:基于临床实践研究数据链的观察性研究

Analgesic prescribing in patients with inflammatory arthritis in England: observational studies in the Clinical Practice Research Datalink.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该研究基于临床实践研究数据链Aurum数据库,对2004至2020年类风湿关节炎、银屑病关节炎和中轴型脊柱关节炎患者的镇痛药处方进行横断面分析、Joinpoint回归趋势分析和Cox比例风险模型队列研究。结果显示镇痛药处方量下降但仍普遍,2020年阿片类药物处方最多,加巴喷丁类药物处方增加,多数阿片类处方为慢性处方。作者认为当前处方既非循证也不符合指南,诊断前后是减少慢性镇痛药处方的有利时机。

要点

  • 2004至2020年炎症性关节炎患者镇痛药处方率从84.2/100人年降至64.5/100人年,但仍普遍。
  • 2020年阿片类药物处方最多(39.0/100人年),加巴喷丁类药物从1.1/100人年增至9.9/100人年。
  • 2020年多数阿片类处方为慢性处方(23.4/100人年),诊断前后是启动慢性处方的高风险期。

核心结论

  • 炎症性关节炎各类镇痛药处方普遍,既非循证也不符合指南。
  • 诊断前后是减少慢性镇痛药处方的有利时机。

研究设计与样本

  • 研究使用临床实践研究数据链Aurum数据库,纳入2004至2020年类风湿关节炎、银屑病关节炎和中轴型脊柱关节炎患者。
  • 采用横断面分析评估镇痛药处方年患病率,按年龄、性别、种族、贫困程度和地理分层。
  • 采用Joinpoint回归评估处方时间趋势。
  • 采用队列研究和Cox比例风险模型确定诊断时慢性镇痛药处方的预后因素。

主要发现

  • 2004年炎症性关节炎镇痛药处方率为84.2/100人年(95%CI 83.9, 84.5),2020年为64.5/100人年(95%CI 64.2, 64.8)。
  • 2004年NSAIDs处方最多(56.1/100人年;95%CI 55.8, 56.5),随后下降;2020年阿片类药物处方最多(39.0/100人年;95%CI 38.7, 39.2)。
  • 加巴喷丁类药物处方从2004年1.1/100人年(95%CI 1.0, 1.2)增至2020年9.9/100人年(95%CI 9.7, 10.0)。
  • 2020年多数阿片类处方为慢性处方(23.4/100人年;95%CI 23.2, 23.6)。
  • 非NSAID镇痛药处方在类风湿关节炎、老年人、女性和贫困地区/英格兰北部更常见;NSAIDs处方在中轴型脊柱关节炎/男性更常见,贫困/地理差异小。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite little evidence that analgesics are effective in inflammatory arthritis (IA), studies report substantial opioid prescribing. The extent this applies to other analgesics is uncertain. We undertook a comprehensive evaluation of analgesic prescribing in patients with IA in the Clinical Practice Research Datalink Aurum to evaluate this. METHODS: From 2004 to 2020, cross-sectional analyses evaluated analgesic prescription annual prevalence in RA, PsA and axial spondyloarthritis (axSpA), stratified by age, sex, ethnicity, deprivation and geography. Joinpoint regression evaluated temporal prescribing trends. Cohort studies determined prognostic factors at diagnosis for chronic analgesic prescriptions using Cox proportional hazards models. RESULTS: Analgesic prescribing declined over time but remained common: 2004 and 2020 IA prescription prevalence was 84.2/100 person-years (PY) (95% CI 83.9, 84.5) and 64.5/100 PY (64.2, 64.8), respectively. In 2004, NSAIDs were most prescribed (56.1/100 PY; 55.8, 56.5), falling over time. Opioids were most prescribed in 2020 (39.0/100 PY; 38.7, 39.2). Gabapentinoid prescribing increased: 2004 prevalence 1.1/100 PY (1.0, 1.2); 2020 prevalence 9.9/100 PY (9.7, 10.0). Most opioid prescriptions were chronic (2020 prevalence 23.4/100 PY [23.2, 23.6]). Non-NSAID analgesic prescribing was commoner in RA, older people, females and deprived areas/northern England. Conversely, NSAID prescribing was commoner in axSpA/males, varying little by deprivation/geography. Peri-diagnosis was high-risk for starting chronic opioid/NSAID prescriptions. Prognostic factors for chronic opioid/gabapentinoid and NSAID prescriptions differed, with NSAIDs having no consistently significant association with deprivation (unlike opioids/gabapentinoids). CONCLUSION: IA analgesic prescribing of all classes is widespread. This is neither evidence-based nor in line with guidelines. Peri-diagnosis is an opportune moment to reduce chronic analgesic prescribing.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Scott IC, Whittle R, Bailey J, et al. Analgesic prescribing in patients with inflammatory arthritis in England: observational studies in the Clinical Practice Research Datalink. Rheumatology (Oxford). 2024. PMID: 37822018. doi:10.1093/rheumatology/kead463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。